Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula

Status Terminated

Clinical Trial Summary

Comparing the vitrification at Day-4 (morula stage) with the blastocyst stage vitrification outcomes with the transfer of all day 5 after warming seems need evaluation. To the best of our knowledge, there has been no random-controlled trial conducted such comparison. Altogether, this trial is to evaluate the morula stage vitrification to blastocyst vitrification on the ongoing pregnancy rate after ICSI.

Clinical Trial Description

Vitrification of human embryos has been a paradigm-shifting procedure for higher survival rate compared with the slow freezing protocol. The evidence is scarce to support superior results for vitrifying certain stages of preimplantation embryos. Anecdotal evidence suggests that blastocyst vitrification is more forgiving than cleavage stages. However, data obtained from the procedure of assisted shrinkage of blastocysts before vitrification show a higher survival rate, suggesting that fluid accumulation insides the blastocyst can be a barrier for cryoprotectant to reach the cells. Although reassuring, whether facilitating the cryoprotectants transfer to cells by the laser-assisted shrinkage or other modalities is completely safe remains elusive. Moreover, other claims compare between day-3 embryos vitrification and blastocyst stage, suggesting no difference exists. One of the most critical stages in embryo development is the maternal to zygotic genome activation (MZA), which occurs at the 4 to 8 cell stages. Therefore, it seems the morula stage is still cleavage but passed the MZA. Morula in the most grading system has compaction for all or the majority of cells so if vitrified, the morula stage can bypass the earlier stage of vitrification as well as the need for the artificial shrinkage for blastocyst stage. Therefore, comparing the vitrification at Day-4 (morula stage) with the blastocyst stage vitrification outcomes with the transfer of all day 5 after warming seems need evaluation. To the best of our knowledge, there has been no random-controlled trial conducted such comparison. Altogether, this trial is to evaluate the morula stage vitrification to blastocyst vitrification on the ongoing pregnancy rate after ICSI. ;

Study Design

Related Conditions & MeSH terms

Infertility

Clinical Trial Details

NCT number	NCT03787901
Study type	Interventional
Source	Egyptian Foundation of Reproductive Endocrinology
Contact
Status	Terminated
Phase	N/A
Start date	January 15, 2019
Completion date	June 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03607409` - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting	`NCT02312076` - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles	Phase 4
Terminated	`NCT02161861` - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study	N/A
Completed	`NCT03287479` - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)	N/A
Terminated	`NCT03522350` - Randomized Trial Comparing EmbryoScope With EmbryoScope+.	N/A
Completed	`NCT04496284` - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen	N/A
Completed	`NCT03623659` - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts	N/A
Completed	`NCT03895099` - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors	Phase 3
Active, not recruiting	`NCT04142112` - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation	N/A
Completed	`NCT03152643` - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer	N/A
Recruiting	`NCT03683771` - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting	`NCT03161119` - Comparing Two Different Embryo Transfer Catheters	N/A
Completed	`NCT04108039` - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.	N/A
Completed	`NCT03678818` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)	N/A
Completed	`NCT03678584` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)	N/A
Completed	`NCT03678597` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)	N/A
Completed	`NCT03678610` - Handling Medium for ICSI With Ionomycin and Latrunculin A	N/A
Completed	`NCT03677492` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)	N/A
Completed	`NCT03678558` - Oocyte Vitrification Aided With Cytochalasin B	N/A
Completed	`NCT03678571` - Oocyte Vitrification Aided With Latrunculin A	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms